FIGURE 3.

Mechanism of Ruxolitinib and dexamethasone on CAR T cells in vitro. A, CD19 CAR T cell expansion model in vitro and CRS model established by co‐culture with 5 × 10⁴ CD19 CAR T cells, 5 × 10⁴ nalm6 (CD19⁺) and 1 × 10⁴ monocytes in vitro. B, The differences of CAR T cell expansion after 48‐h coculture under different drug concentrations (0, Ruxo 1 umol/L, Ruxo 10 umol/L, Dex 1 umol/L, Dex 10 umol/L). C, The differences of cytokines levels (IL‐6, TNFα, IL‐10, INFγ, sFas and Granzyme B) in supernatant liquid of 48‐hour co‐culture with CD19 CAR T cells, monocytes and Nalm6 cells under different drug concentrations (0, Ruxo 1 umol/L, Ruxo 10 umol/L, Dex 1 umol/L, Dex 10 umol/L), and T cells with pCDH vector, monocytes and Nalm6 cells (CD19⁺) were coculutre as negative control. In B and C panels, the difference is compared by unpaired two‐tailed Student's t test. P‐values of <.05 were considered significant. Ruxo represents ruxolitinib and Dex represents dexamethasone